Home / Knowledge Centre /

Predictive assay for anti-angiogenic agents (AADx) identifies a molecular subgroup of RAS wt mCRC with low efficacy of FOLFIRI plus bevacizumab – analysis of the FIRE-3 (AIO KRK-0306) trial

The data suggests that the AADx assay interacts with RAS mutation and may define RAS wild-type mCRC patients that respond differently to cetuximab or bevacizumab in combination with FOLFIRI. One potential explanation of the data is that Cetuximab is a more effective treatment for the poor prognosis ANGIO ON subtype.

View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies